ReviewSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2023
SPECT/CT and PET/CT, related radiopharmaceuticals, and areas of application and comparison.
Review in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Stable core-encapsulation of indium-111 in crosslinked polyionic complex micelles and assessment of its biodistribution.EJNMMI radiopharmacy and chemistry · 2026Article
- Intraoperative molecular imaging - it's all about advancing surgical decision making and improving dexterity.Zeitschrift fur medizinische Physik · 2026Review
- EfficientInternational journal of molecular sciences · 2026Article
- STING-Activating nanoplatforms for image-guided sonodynamic cancer therapy.Molecular cancer · 2026Article
- Advancements in Targeted Radiopharmaceuticals: Innovations in Diagnosis and Therapy for Enhanced Cancer Management.Chembiochem : a European journal of chemical biology · 2026Review
- A Novel FAPI-Based Radiopharmaceutical for SPECT Imaging of Fibrotic Interstitial Lung Disease.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Preclinical Positron Emission Tomography Imaging of B7-H3 Expression Using Affibody Molecules Labeled with Gallium-68.ACS pharmacology & translational science · 2025Article
- The Role of Artificial Intelligence in Advancing Theranostics Dosimetry for Cancer Therapy: a Review.Nuclear medicine and molecular imaging · 2025Review
- Recent advances in copper sulfide nanoparticles for cancer diagnosis and therapy.Materials today. Bio · 2025Review
- Development of New NanoAlbumin-based Radiotracers: Preclinical Evaluation Of [Molecular imaging and biology · 2025Article
- Design and Preclinical Validation of an Anti-B7-H3-Specific Radiotracer: A Non-Invasive Imaging Tool to Guide B7-H3-Targeted Therapies.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Production, Validation, and Exposure Dose Measurement of [Pharmaceutics · 2025Article
- Current Concepts in the Management and Treatment of Spinal Metastases-A Systematic Literature Review.Cancers · 2025Review
- Theranostics in Hematological Malignancies: Cutting-Edge Advances in Diagnosis and Targeted Therapy.Cancers · 2025Review
- Review
- Exploring Radioiodinated Anastrozole and Epirubicin as AKT1-Targeted Radiopharmaceuticals in Breast Cancer: In Silico Analysis and Potential Therapeutic Effect with Functional Nuclear Imagining Implications.Molecules (Basel, Switzerland) · 2024Article
- Article
- Nuclear Cardiology in the Era of Precision Medicine: Tailoring Treatment to the Individual Patient.Cureus · 2024Review
- Insights into Peptidoglycan-Targeting Radiotracers for Imaging Bacterial Infections: Updates, Challenges, and Future Perspectives.ACS infectious diseases · 2024Review
- Recent advances in positron emission tomography for detecting early fibrosis after myocardial infarction.Frontiers in cardiovascular medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The paper begins by identifying the key historical elements in the development of nuclear medicine imaging, focusing on the Anger camera and single photon emission computed tomography (SPECT) technologies. In this context, key reference is made to the physics of detection in Anger camera systems, especially key components such as the sodium iodide crystal, the function and performance of photomultiplier tubes, and the collimator design. It is discovered that within each component of technology, there are fundamental physical relationships that govern the performance of each component, and that overall image quality is the result of the complex interaction of all such elements. The increasing use of SPECT/CT imaging is described and illustrated with a range of typical clinical applications, which include brain, spinal, cardiac, and cancer studies. The use of CT imaging functionality allows for SPECT image correction based on compensation for absorption within tissue. Reference is also made to the basics of positron emission tomography (PET) imaging and, in particular, to the integration of PET/CT systems where the anatomy profile of the CT image is used to provide correction for photon absorption. A summary is provided of the radionuclides and radiopharmaceuticals commonly used in PET/CT imaging and a range of image studies referenced includes those of nasopharyngeal carcinoma, lung cancer investigation, brain investigation (cancer detection and dementia) and cardiac function. Reference is made to the development of "time of flight" (TOF) technology for improving of image resolution in PET/CT systems. Furthermore, SPECT/CT and PET/CT imaging systems are compared, where a key factor identified is the significantly higher number of photons detected with PET/CT technology and improved image resolution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.